The merger of two pioneers of psychedelic medicines has completed with the creation of AtaiBeckley, a company with a pipeline ...
Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...
"The UK's inability to retain economic benefits of its R&D is a fatal flaw to any growth strategy," according to the document ...
The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...
This article aims to share how to build an effective healthcare content strategy that boosts online patient engagement and ...
Shares in Metsera shot up nearly 20% to more than $72 after news of the renewed bidding war emerged, raising its market ...
Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...
The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...
That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...
The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...
Today, POA Pharma is headquartered in Copenhagen, with additional facilities located across the Nordics and Germany. Galen ...
France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve patient outcomes in a phase 3 study, which has now been terminated. Genfit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback